Vesiculobullous skin disease
MONDO:0006617Skin diseases characterized by local or general distributions of blisters. They are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. (From Scientific American Medicine, 1990)
Also known as: vesiculobullous skin disease, Sneddon Wilkinson disease, Sneddon-Wilkinson disease, skin diseases, vesicular, subcorneal pustular dermatoses, subcorneal pustular dermatosis, bullous dermatoses, bullous skin disease
193 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a new vaccine beat chickenpox? large trial underway
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new chickenpox vaccine called NBP608 in about 780 children aged 1 to 12 years. The vaccine is compared to licensed vaccines to see how well it triggers immunity and if it is safe. Children receive one or two shots, and researchers monitor their immune response …
Phase: PHASE3 • Sponsor: SK Bioscience Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
New chickenpox vaccine trial aims to protect 300 kids
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new chickenpox vaccine in 300 healthy children aged 1 to 12 years. All children will receive one dose of the vaccine. Researchers will check if the vaccine triggers a strong immune response and is safe to use.
Phase: PHASE3 • Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:07 UTC
-
New combo vaccine for kids could replace current shot
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new vaccine that protects against measles, mumps, rubella, and chickenpox (MMRV) in healthy children aged 15 months to 6 years. It compares the new vaccine to an already approved one (ProQuad) to see if it works as well and is safe. About 1,200 children will re…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
New mRNA shingles vaccine enters phase 2 trial – could it be a game changer?
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a new mRNA vaccine called SYS6017 to prevent shingles, a painful rash caused by the chickenpox virus. About 800 healthy adults aged 40 and older will receive either the new vaccine, a placebo, or an existing shingles vaccine. Researchers will check how well the v…
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:12 UTC
-
MRNA vaccine aims to prevent shingles in older adults
⭐️ VACCINE ⭐️ Not yet recruitingThis phase 2 trial tests a new mRNA vaccine called IN001 for preventing shingles in healthy adults aged 50 to 79. Researchers will compare three dose levels of IN001 against the existing Shingrix vaccine to see how safe and effective they are. The study involves 480 participants …
Phase: PHASE2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:54 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Phase: PHASE4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Stop the pills when symptoms vanish? landmark trial for Kids' infections
Disease control Not yet recruitingThis study tests whether children with bacterial infections like urinary tract infections, cellulitis, or pneumonia can safely stop oral antibiotics once their symptoms go away, instead of finishing the entire course. About 200 children aged 1 to 17 who have already received IV a…
Phase: PHASE4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Eye surgery breakthrough? tiny trial tests humira injection during corneal implant
Disease control Not yet recruitingThis early-stage trial will test whether injecting adalimumab (Humira) into the eye during Boston KPro surgery is safe for 8 patients with severe corneal damage. The study focuses on side effects and tolerability, not yet on how well it works. It is for people who have run out of…
Phase: PHASE1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New cream could help kids with 'Butterfly Skin' heal faster
Disease control Not yet recruitingThis phase 3 trial tests whether a cream called SD-101 can help close wounds in children with epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. About 80 children aged 1 month to 12 years will apply the cream or a placebo to their whole body for 2 month…
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New shot could help patients with severe blistering skin disease ditch steroids
Disease control Not yet recruitingThis study tests an injection called stapokibart for people with moderate to severe bullous pemphigoid, a painful blistering skin condition. The goal is to see if it can help patients stop taking steroids and keep the disease under control for 36 weeks. About 200 adults aged 18 t…
Phase: PHASE3 • Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Phase: PHASE1, PHASE2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
Can a simple blood test spot hidden heart trouble during High-Pressure oxygen treatment?
Diagnosis Not yet recruitingThis study looks at whether a blood gas measurement (the difference in carbon dioxide between central venous and arterial blood) can accurately diagnose low cardiac output in patients with septic shock from severe skin infections. About 74 adults will be monitored during hyperbar…
Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Shingles breakthrough? calcitonin shots aim to stop chronic pain before it starts
Prevention Not yet recruitingThis phase 3 trial tests whether adding daily calcitonin injections to standard shingles treatment can prevent postherpetic neuralgia, a painful nerve condition that can last for months or years. Researchers will enroll 168 adults aged 50 and older who have had a shingles rash fo…
Phase: PHASE3 • Sponsor: Tanta University • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New shingles shot shows promise in Mid-Stage trial
Prevention Not yet recruitingThis study tests a new shingles vaccine in 135 healthy adults aged 50 and older. Researchers will compare the immune response and safety of the new vaccine against an existing one to find the best dose. The goal is to prevent shingles, a painful rash caused by the chickenpox viru…
Phase: PHASE2 • Sponsor: CHA Vaccine Institute Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Could a booster shot shield transplant patients from shingles?
Prevention Not yet recruitingThis study tests whether an extra dose of the shingles vaccine (Shingrix) can boost immunity in people who have had a solid-organ transplant, like a kidney or liver. About 30% of transplant patients still get shingles after the standard two-dose vaccine, likely due to immune-supp…
Phase: PHASE2 • Sponsor: Oriol Manuel • Aim: Prevention
Last updated Jun 27, 2026 09:09 UTC
-
Don't wash that baby! study tests if keeping vernix on prevents eczema
Prevention Not yet recruitingThis study tests whether leaving the white, creamy coating (vernix caseosa) on a newborn's skin for at least 24 hours after birth can prevent eczema (atopic dermatitis) during the first year of life. Over 1,300 mother-infant pairs in Chile will be randomly assigned to either keep…
Phase: NA • Sponsor: Pontificia Universidad Catolica de Chile • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
Shingles vaccine tested for lung cancer patients: could it boost survival?
Prevention Not yet recruitingThis study looks at whether the shingles vaccine can prevent shingles and improve survival in 500 lung cancer patients. Participants will either receive the vaccine or not, and researchers will track shingles cases and survival rates over time. The goal is to see if the vaccine o…
Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Prevention
Last updated Jun 26, 2026 16:12 UTC
-
Could a common painkiller speed up cellulitis recovery?
Symptom relief Not yet recruitingCellulitis is a painful bacterial skin infection. This study tests whether adding naproxen (an anti-inflammatory drug) to standard antibiotics helps reduce redness and pain faster than antibiotics alone. About 884 adults with cellulitis will take either naproxen or a placebo for …
Phase: PHASE3 • Sponsor: Ottawa Hospital Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New gel promises shingles pain relief in minutes
Symptom relief Not yet recruitingThis study tests a special gel applied to the skin to see if it can quickly reduce pain from shingles. Thirty adults with shingles-related pain will receive a single application of the gel. Researchers will measure pain levels before and after application, focusing on relief with…
Phase: NA • Sponsor: Nakhia Impex LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Could a simple ingredient boost dry eye drops?
Symptom relief Not yet recruitingThis study tests if adding sodium hyaluronate (a common moisturizer in artificial tears) to autologous serum eye drops provides better relief for moderate-to-severe dry eye disease. About 20 adults with dry eye from conditions like Sjögren's syndrome will use the new mix in one e…
Phase: PHASE2 • Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New cream aims to soothe butterfly skin in Late-Stage trial
Symptom relief Not yet recruitingThis Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Could a common steroid help kids with severe eye infections?
Symptom relief Not yet recruitingThis pilot study tests whether giving dexamethasone (a steroid) to children hospitalized with orbital cellulitis (a serious eye infection) is worth studying further. Thirty children will receive either dexamethasone or a placebo by IV. The main goal is to see if a larger trial is…
Phase: NA • Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Could a steroid injection stop shingles pain for good?
Symptom relief Not yet recruitingThis study tests whether dexamethasone palmitate, a steroid, can better relieve shingles pain and prevent long-term nerve pain compared to standard care. About 954 adults with shingles rash and severe pain will receive the drug by injection or infusion. Researchers will track pai…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Skin deep: european study probes the hidden emotional toll of skin diseases
Knowledge-focused Not yet recruitingThis study looks at how people with skin conditions (like eczema, psoriasis, or skin cancer) manage stress, feel lonely, and bounce back from challenges. Researchers will compare 375 adults with and without skin disease across 15 European countries using questionnaires. The goal …
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Statins vs. smoke: can a pill protect your heart and brain?
Knowledge-focused Not yet recruitingThis study tests whether taking statins (a common cholesterol drug) can protect the heart and brain from the harmful effects of breathing bushfire smoke. Healthy adults aged 18-64 will be exposed to simulated smoke in a controlled setting, with some taking statins short-term (2 d…
Phase: PHASE4 • Sponsor: Menzies Institute for Medical Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Scientists hunt for biomarkers to unlock rare eye disease treatments
Knowledge-focused Not yet recruitingThis study aims to find biological markers (biomarkers) in blood, tears, and eye cells from 110 adults with seven rare eye diseases. Researchers will compare these markers between patients and healthy controls to see if they differ and if they relate to disease symptoms. The goal…
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC